Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJun 10, 2026
DataAggregated Company Financials
Companies184
  • 7D1.2%
  • 3M6.5%
  • 1Y6.7%
  • YTD8.4%

Over the last 7 days, the Pharma industry has risen 1.2%, driven by gains from Torrent Pharmaceuticals of 2.1%. In the same time, Wockhardt was down 12%. This takes the industry's 12 month performance to a gain of 6.7%. Earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 10 Jun 2026₹22.2t₹4.5t₹643.0b28.7x34.5x4.9x
Fri, 08 May 2026₹21.8t₹4.4t₹622.6b29.7x35.1x5x
Sun, 05 Apr 2026₹19.6t₹4.3t₹621.1b26.4x31.6x4.5x
Tue, 03 Mar 2026₹20.5t₹4.3t₹621.2b26.4x32.9x4.7x
Thu, 29 Jan 2026₹19.5t₹4.2t₹605.1b28.8x32.2x4.6x
Sat, 27 Dec 2025₹20.4t₹4.2t₹614.5b28.6x33.2x4.8x
Mon, 24 Nov 2025₹20.3t₹4.2t₹611.6b29.7x33.3x4.8x
Wed, 22 Oct 2025₹20.5t₹4.1t₹590.3b30.4x34.8x5x
Fri, 19 Sep 2025₹20.7t₹4.1t₹587.9b31.9x35.1x5.1x
Sun, 17 Aug 2025₹20.3t₹4.1t₹589.0b30.4x34.5x5x
Tue, 15 Jul 2025₹20.8t₹4.0t₹594.1b32.9x35x5.2x
Thu, 12 Jun 2025₹20.5t₹4.0t₹595.3b33.2x34.4x5.2x
Sat, 10 May 2025₹19.1t₹3.9t₹562.9b28.4x33.9x4.9x
Mon, 07 Apr 2025₹18.9t₹3.9t₹559.2b28.6x33.8x4.9x
Wed, 05 Mar 2025₹18.2t₹3.9t₹559.4b27x32.4x4.7x
Fri, 31 Jan 2025₹19.6t₹3.9t₹537.7b31.2x36.4x5.1x
Sun, 29 Dec 2024₹21.1t₹3.8t₹527.0b35.3x40x5.5x
Tue, 26 Nov 2024₹20.5t₹3.8t₹526.7b34.2x38.9x5.4x
Thu, 24 Oct 2024₹20.7t₹3.7t₹492.6b37.5x42x5.6x
Sat, 21 Sep 2024₹21.4t₹3.7t₹492.6b41.1x43.4x5.7x
Mon, 19 Aug 2024₹20.4t₹3.8t₹492.5b36.1x41.4x5.4x
Wed, 17 Jul 2024₹18.8t₹3.6t₹449.9b34.7x41.7x5.2x
Fri, 14 Jun 2024₹17.6t₹3.6t₹448.3b33x39.3x4.9x
Sun, 12 May 2024₹16.7t₹3.5t₹428.7b33.4x39x4.8x
Tue, 09 Apr 2024₹17.2t₹3.5t₹418.9b33.5x41.1x4.9x
Thu, 07 Mar 2024₹17.0t₹3.5t₹418.7b33x40.7x4.9x
Sat, 03 Feb 2024₹16.1t₹3.4t₹405.3b34.6x39.8x4.7x
Mon, 01 Jan 2024₹15.0t₹3.4t₹395.9b34.1x37.8x4.4x
Wed, 29 Nov 2023₹14.0t₹3.4t₹395.1b31x35.5x4.1x
Fri, 27 Oct 2023₹12.7t₹3.3t₹368.8b28x34.4x3.9x
Sun, 24 Sep 2023₹12.9t₹3.3t₹369.5b29.7x35x4x
Tue, 22 Aug 2023₹13.0t₹3.3t₹367.1b28.8x35.5x4x
Thu, 20 Jul 2023₹12.1t₹3.2t₹342.6b26.2x35.3x3.8x
Sat, 17 Jun 2023₹11.4t₹3.2t₹342.4b27.1x33.2x3.6x
Price to Earnings Ratio

33.2x


Total Market Cap: ₹11.4tTotal Earnings: ₹342.4bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-0.68%
Healthcare1.85%
Pharma1.20%
Pharma1.20%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
500420 Torrent Pharmaceuticals₹4.46k2.1%
+₹31.7b		39.2%PE69.8x
524742 Caplin Point Laboratories₹2.31k16.9%
+₹25.3b		9.1%PE27.4x
ZYDUSLIFE Zydus Lifesciences₹1.10k2.0%
+₹21.8b		12.2%PE21.9x
IPCALAB Ipca Laboratories₹1.63k4.9%
+₹19.2b		17.3%PE36.2x
AJANTPHARM Ajanta Pharma₹3.07k5.0%
+₹18.2b		16.2%PE36.4x

Latest News

STAR
₹978.20
Strides Pharma Science
7D
-9.5%
1Y
12.7%
524742
₹2,308.00
Caplin Point Laboratories
7D
16.9%
1Y
9.1%
CONCORDBIO
₹1,330.70
Concord Biotech
7D
10.8%
1Y
-37.5%
Analysis Article • 23h

Time To Worry? Analysts Just Downgraded Their Concord Biotech Limited (NSE:CONCORDBIO) Outlook

One thing we could say about the analysts on Concord Biotech Limited ( NSE:CONCORDBIO ) - they aren't optimistic...
GLENMARK
₹2,144.40
Glenmark Pharmaceuticals
7D
-1.4%
1Y
31.1%
Narrative Update • Jun 07

GLENMARK: US Respiratory And Allergy Approvals Will Support Future Upside

Analysts have maintained Glenmark Pharmaceuticals' fair value estimate at ₹2,735.00, and have updated their assumptions to reflect expectations of 10.47% revenue growth, a 14.62% profit margin, and a higher future P/E of 32.71x. What's in the News Board meeting scheduled for May 29, 2026, at 16:30 IST to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a potential equity dividend for the year.
RUBICON
₹1,188.10
Rubicon Research
7D
-6.6%
1Y
n/a
Analysis Article • Jun 06

We Think That There Are Issues Underlying Rubicon Research's (NSE:RUBICON) Earnings

Rubicon Research Limited's ( NSE:RUBICON ) stock was strong after they recently reported robust earnings. However, we...
500257
₹2,248.70
Lupin
7D
-0.5%
1Y
10.9%
530549
₹558.70
Shilpa Medicare
7D
8.3%
1Y
14.6%
Narrative Update • Jun 05

530549: Upcoming Board Actions Will Shape Dividends And Future Earnings Profile

Analysts have modestly raised the price target for Shilpa Medicare from ₹517 to ₹530.5, pointing to updated assumptions that include a slightly higher discount rate, lower projected revenue growth and profit margins, and a higher future P/E multiple. What's in the News The board has scheduled a meeting on 22 May 2026 to consider and approve the audited standalone and consolidated financial results for the fourth quarter and full year ended 31 March 2026, along with the statutory audit report, and to consider a dividend recommendation for the 2025-2026 financial year (source: company board meeting agenda).
500420
₹4,463.30
Torrent Pharmaceuticals
7D
2.1%
1Y
39.2%
Narrative Update • Jun 04

500420: Diabetes And Obesity Portfolio Expansion Will Drive A More Upbeat Outlook

Analysts have raised their indicative fair value estimate for Torrent Pharmaceuticals from about ₹4,565 to roughly ₹4,879, reflecting expectations of steadier revenue growth, a higher profit margin, and a slightly richer future P/E assumption. What's in the News A board meeting is scheduled for 22 May 2026 to consider the audited financial results for the year ended 31 March 2026, a final dividend recommendation for 2025-26, potential fund raising via equity or convertible instruments, and other business matters.
506943
₹2,203.70
J. B. Chemicals & Pharmaceuticals
7D
3.0%
1Y
28.3%
Narrative Update • Jun 04

506943: Dividend Decision And Margin Outlook Will Shape A Steady Future

Analysts have inched up their price target for J. B.
IPCALAB
₹1,630.20
Ipca Laboratories
7D
4.9%
1Y
17.3%
Narrative Update • Jun 04

IPCALAB: Higher Fair Value And Board Review Will Support Future Upside Potential

Analysts now set a higher fair value price target for Ipca Laboratories at ₹1,887, compared with ₹1,731 earlier, reflecting updated assumptions on revenue growth, profit margins and future P/E levels. What's in the News A board meeting is scheduled for May 29, 2026, to review standalone and consolidated audited financial results for the fourth quarter and full year ended March 31, 2026.
WOCKPHARMA
₹1,833.00
Wockhardt
7D
-11.6%
1Y
0.1%
NATCOPHARM
₹854.60
NATCO Pharma
7D
-8.6%
1Y
-8.5%
Narrative Update • Jun 02

NATCOPHARM: Diabetes Injection Launch And Demerger Will Drive Future Upside

Analysts now set a lower price target for NATCO Pharma at ₹1,220 compared with the previous fair value of ₹1,391, citing updated assumptions around revenue growth, profitability, and a recalibrated future P/E multiple. What's in the News NATCO Pharma issued earnings guidance for 2027, indicating expected revenue in the range of ₹34,000 million to ₹35,000 million (Corporate Guidance).
ZYDUSLIFE
₹1,098.30
Zydus Lifesciences
7D
2.0%
1Y
12.2%
Narrative Update • Jun 02

ZYDUSLIFE: Buyback And Specialty Pipeline Progress Will Shape A Balanced Outlook

Analysts have lifted their price target on Zydus Lifesciences from ₹985.41 to ₹1,066.50, citing updated assumptions that point to different expectations for revenue growth, profit margins, and the future P/E multiple. What's in the News The board has approved a share buyback plan, with the company set to repurchase up to 8,730,158 shares (about 0.87% of outstanding equity) for a total of ₹11,000m at ₹1,260 per share.
AJANTPHARM
₹3,074.90
Ajanta Pharma
7D
5.0%
1Y
16.2%
Narrative Update • May 30

AJANTPHARM: Overseas Expansion And Ireland Subsidiary Will Likely Cap Future Upside

Ajanta Pharma's analyst price target has shifted from ₹2,605 to about ₹2,701. Analysts point to updated views on fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers behind this change.
532482
₹760.80
Granules India
7D
-4.1%
1Y
41.8%
Narrative Update • May 28

532482: Fair Value Will Depend On Margins And Dividend Sustainability

Analysts have lifted their price target on Granules India from ₹799 to ₹856, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News The board meeting is scheduled for April 29, 2026 to consider and approve audited financial results for Q4 and the full year ended March 31, 2026, and to consider a final dividend for FY 2025-26, if any (Key Developments).
506820
₹8,304.35
AstraZeneca Pharma India
7D
-2.9%
1Y
-16.8%